US OptionsDetailed Quotes
AQST240920P3000
- 0.10
- +0.02+25.00%
15min DelayClose Sep 17 16:00 ET
0.10High0.10Low
0.10Open0.08Pre Close30 Volume188 Open Interest3.00Strike Price300.00Turnover499.93%IV39.46%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0905Delta0.0822Gamma47.90Leverage Ratio-0.0611Theta0.0000Rho-4.34Eff Leverage0.0006Vega
Aquestive Therapeutics Stock Discussion
Top of cloud bounce would like it break the 4.39 Resistance/ Above 4.4 Tenkan Sen. Once Broken target 4.98 then 6.08.
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
Aquestive Therapeutics (NASDAQ: AQST) has commented on the FDA's recent approval of the first non-injection-based epinephrine device for treating severe allergic reactions, including anaphylaxis. The company views this as a positive development for patients seeking altern...
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Aquestive Therapeutics (NASDAQ:AQST) reported its Q2 2024 financial results and shared business updates. Key highlights include:
Anaphylm™ (epinephrine) Sublingual Film remains on track for FDA submission in early 2025, with a potential launch by late 2025 or early 2026.
Positive topline pharmacokinetic (PK) and pharmacodynamic (PD) data reported, showing no ...
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies (DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals (XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
No comment yet